Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1594-1601

  Rezvani, Andrew R ^a   Storer, Barry E ^a   Storb, Rainer F ^a   Mielcarek, Marco ^a   Maloney, David G ^a   Sandmaier, Brenda M ^a   Martin, Paul J ^a   McDonald, George B ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Biomarkers; Graft versus host disease; Prognostic markers; Reduced intensity conditioning

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; DISEASE COURSE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PREOPERATIVE EVALUATION; REDUCED INTENSITY CONDITIONING; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 80054856554     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.021     Document Type: Article

References (25)

1. Burroughs L., Mielcarek M., Leisenring W., et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006, 81:818-825.
2. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391.
3. Sormani M.P., Oneto R., Bruno B., et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003, 32:205-211.
4. Lunn R.A., Sumar N., Bansal A.S., Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology 2005, 10:107-114.
5. Mischak-Weissinger E.M., Holler E., Schleuning M., et al. Prospective evaluation of an aGVHD-specific proteomic pattern in more than 340 patients. Blood 2009, 114:147. abstract 347.
6. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
7. Weissinger E.M., Schiffer E., Hertenstein B., et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007, 109:5511-5519.
8. Srinivasan R., Daniels J., Fusaro V., et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006, 34:796-801.
9. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
10. Weisdorf S.A., Salati M., Longsdorf J.A., Ramsay N.K.C., Sharp H.L. Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal α-antitrypsin. Gastroenterology 1983, 85:1076-1081.
11. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003, 102:2021-2030.
12. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
13. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101:1620-1629.
14. Sandmaier B.M., Maris M., Storer B., et al. A randomized 3-arm phase II study to determine the most promising postgrafting immunosuppression for prevention of acute graft-versus-host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT) using nonmyeloablative conditioning for patients with hematologic malignancies: a multi-center trial. Blood 2009, 114:147. abstract 348.
15. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
16. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
17. Mielcarek M., Burroughs L., Leisenring W., et al. Prognostic relevance of " early-onset" graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br J Haematol 2005, 129:381-391.
18. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications 1996, Academic Press, San Diego, CA.
19. Epstein R.J., McDonald G.B., Sale G.E., Shulman H.M., Thomas E.D. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology 1980, 78:764-771.
20. Fisk J.D., Shulman H.M., Greening R.R., McDonald G.B., Sale G.E., Thomas E.D. Gastrointestinal radiographic features of human graft-vs.-host disease. Am J Roentgenol 1981, 136:329-336.
21. Venkatasubramanian J., Rao M.C., Sellin J.H. Intestinal electrolyte absorption and secretin. Sleisinger and Fordtran's Gastroinstestinal and Liver Disease: Pathophysiology, Diagnosis, Management 2010, 1675-1694. Saunders Elsevier, Philadelphia, PA. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
22. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005, 106:1495-1500.
23. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006, 108:749-755.
24. Castilla-Llorente C., Nash R.A., McDonald G.B., Storer B.E., Martin P.J. Prognostic factors and outcomes of severe gastrointestinal graft-vs-host disease (GI GVHD) after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15(Suppl):S120-S121.
25. Nishiwaki S., Terakura S., Ito M., et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 2009, 114:3113-3116.